Preoperative hemoglobin and outcomes in patients with CKD undergoing cardiac surgery

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 9, 2014, Pages 1536-1544

  Shavit, Linda ^a   Hitti, Sharbel ^a   Silberman, Shuli ^a   Tauber, Rachel ^a   Merin, Ofer ^a   Lifschitz, Meyer ^a   Slotki, Itzchak ^a   Bitran, Daniel ^a   Fink, Daniel ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; VERY ELDERLY; BLOOD; CHRONIC KIDNEY FAILURE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; TREATMENT OUTCOME;

AGED; CARDIAC SURGICAL PROCEDURES; FEMALE; HEMOGLOBINS; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84923803866     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00110114     Document Type: Article

References (24)

1. Barrett BJ, Fenton SS, Ferguson B, Halligan P, Langlois S, Mccready WG, Muirhead N, Weir RV; Canadian Society of Nephrology: Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. J Am Soc Nephrol 10[Suppl 13]: S292–S296, 1999.
2. KDOQI; National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47[Suppl 3]: S11–S145, 2006.
3. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085–2098, 2006.
4. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071–2084, 2006.
5. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584–590, 1998.
6. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019–2032, 2009.
7. US Food and Drug Administration: Ongoing Safety Review Erythropoiesis-Stimulating Agents (ESAs) Epoetin Alfa (Marketed as Procrit, Epogen) and Darbepoetin Alfa (Marketed as Aranesp): Update, US Department of Health & Human Services, 2013, US Food and Drug Administration.
8. KDIGO: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2: 279–335, 2012.
9. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, Hiesmayr M: Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: Aprospective cohort study. JAmSocNephrol 15: 1597–1605, 2004.
10. Cooper WA, O’Brien SM, Thourani VH, Guyton RA, Bridges CR, Szczech LA, Petersen R, Peterson ED: Impact of renal dysfunction on outcomes of coronary artery bypass surgery: Results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 113: 1063–1070, 2006.
11. Ranucci M, Di Dedda U, Castelvecchio S, Menicanti L, Frigiola A, Pelissero G; Surgical and Clinical Outcome Research (SCORE) Group: Impact of preoperative anemia on outcome in adult cardiac surgery: A propensity-matched analysis. Ann Thorac Surg 94: 1134–1141, 2012.
12. Karkouti K, Wijeysundera DN, Yau TM, Callum JL, Cheng DC, Crowther M, Dupuis JY, Fremes SE, Kent B, Laflamme C, Lamy A, Legare JF, Mazer CD, McCluskey SA, Rubens FD, Sawchuk C, Beattie WS: Acute kidney injury after cardiac surgery: Focus on modifiable risk factors. Circulation 119: 495–502, 2009.
13. Karkouti K, Wijeysundera DN, Beattie WS; Reducing Bleeding in Cardiac Surgery (RBC) Investigators: Risk associated with preoperative anemia in cardiac surgery: A multicenter cohort study. Circulation 117: 478–484, 2008.
14. Kulier A, Levin J, Moser R, Rumpold-Seitlinger G, Tudor IC, Snyder-Ramos SA, Moehnle P, Mangano DT; Investigators of the Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation: Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 116: 471–479, 2007.
15. Cladellas M, Bruguera J, Comín J, Vila J, de Jaime E, Martí J, Gomez M: Is pre-operative anaemia a risk marker for in-hospital mortality and morbidity after valve replacement? Eur Heart J 27: 1093–1099, 2006.
16. Zindrou D, Taylor KM, Bagger JP: Preoperative haemoglobin concentration and mortality rate after coronary artery bypass surgery. Lancet 359: 1747–1748, 2002.
17. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107: 294–299, 2003.
18. Bolger AP, Bartlett FR, Penston HS, O’Leary J, Pollock N, Kaprielian R, Chapman CM: Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48: 1225–1227, 2006.
19. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Schwartz I, Steinbruch S, Iaina A: The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18: 141–146, 2003.
20. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35: 1737–1744, 2000.
21. Cladellas M, Farre´ N, Comín-Colet J, Gómez M, Merõno O, Bosch MA, Vila J, Molera R, Segovia A, Bruguera J: Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement. Am J Cardiol 110: 1021–1026, 2012.
22. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesisstimulating agents—time for a reevaluation. N Engl J Med 362: 189–192, 2010.
23. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363: 1146–1155, 2010.
24. Dunne JR, Malone D, Tracy JK, Gannon C, Napolitano LM: Perioperative anemia: An independent risk factor for infection, mortality, and resource utilization in surgery. J Surg Res 102: 237–244, 2002.